What the FDA labels say about taking them together
Nalbuphine and oxymorphone
Oxymorphone's FDA label of June 29, 2026 names nalbuphine in its drug interactions section; nalbuphine's label does not name oxymorphone itself but warns about its class (Opioids (opioid agonists)). The oxymorphone label: “Additionally, avoid the use of mixed agonist/antagonist or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including oxymorphone hydrochloride tablets.”
Check it at the source: the nalbuphine FDA label on DailyMed (effective December 31, 2025, Hospira, Inc.); the oxymorphone FDA label on DailyMed (effective June 29, 2026, Aurolife Pharma, LLC).
What does the nalbuphine label say about oxymorphone?
Nalbuphine's label does not name oxymorphone itself; it warns about its class (Opioids (opioid agonists)):
Nalbuphine label, warningsLife-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended.
Nalbuphine label, boxed warningSERIOUS AND LIFE-THREATENING RISKS FROM USE OF NALBUPHINE HYDROCHLORIDE INJECTION Addiction, Abuse, and Misuse Because the use of Nalbuphine Hydrochloride Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see WARNINGS ].
Source: FDA drug label (Nalbuphine Hydrochloride), Hospira, Inc., effective December 31, 2025 (SPL set 6025e8d4-5083-4c3a-58a0-050e7b0b6150), via openFDA; the full label on DailyMed
What does the oxymorphone label say about nalbuphine?
Oxymorphone label, drug interactionsExamples; butorphanol, nalbuphine, pentazocine, buprenorphine,
Oxymorphone label, warnings and precautionsAdditionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including oxymorphone hydrochloride tablets.
Source: FDA drug label (Oxymorphone Hydrochloride), Aurolife Pharma, LLC, effective June 29, 2026 (SPL set 22c7652a-aa16-4fa8-89d9-517e69059068), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nalbuphine | Oxymorphone | |
|---|---|---|
| Labeled for | Pain | Pain |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $4.32 per mL 10 mg/mL ampul | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once